Andrea Scozzafava

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9754/andrea-scozzafava-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

640 papers	37,516 citations	102 h-index	155 g-index
690 ext. papers	39,297 ext. citations	4.7 avg, IF	7.23 L-index

#	Paper	IF	Citations
640	Treatment of NSAPs-rich petrochemical wastewaters using a two-stage combined process of fungi and activated sludge. *Environmental Technology (United Kingdom)*, **2021**, 42, 3783-3796	2.6	0
639	Mechanism of action of carbonic anhydrase inhibitors **2019**, 245-255		1
638	Sulfonamide carbonic anhydrase inhibitors: Zinc coordination and tail effects influence inhibitory efficacy and selectivity for different isoforms. *Inorganica Chimica Acta*, **2018**, 470, 128-132	2.7	6
637	Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis. *Journal of Medicinal Chemistry*, **2018**, 61, 4961-4977	8.3	37
636	Sulphonamide inhibition studies of the β-carbonic anhydrase from the bacterial pathogen Clostridium perfringens. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 31-36	5.6	12
635	Dioxygen, an unexpected carbonic anhydrase ligand. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 999-1005	5.6	12
634	Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis. *Journal of Medicinal Chemistry*, **2017**, 60, 1159-1170	8.3	94
633	The crystal structures of native hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3 and of substrate and inhibitor complexes. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2017**, 1865, 520-530	4	1
632	Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. *Neuropharmacology*, **2017**, 118, 148-156	5.5	57
631	1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 4560-4565	3.4	10
630	The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. *Journal of Enzyme Inhibition and Medicinal Chemistry*,	5.6	101
629	Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2016**, 31, 205-11	5.6	14
628	Monothiocarbamates Strongly Inhibit Carbonic Anhydrases in Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma. *Journal of Medicinal Chemistry*, **2016**, 59, 5857-67	8.3	47
627	Kinetic and X-ray crystallographic investigations of substituted 2-thio-6-oxo-1,6-dihydropyrimidine-benzenesulfonamides acting as carbonic anhydrase inhibitors. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3643-8	3.4	12
626	Dithiocarbamates with potent inhibitory activity against the Saccharomyces cerevisiae β-carbonic anhydrase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2016**, 31, 132-6	5.6	15
625	Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase isoenzymes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2016**, 31, 1698-702	5.6	134
624	Sulfonamide inhibition studies of the β-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 1253-9	2.9	11

623	Thioxocoumarins Show an Alternative Carbonic Anhydrase Inhibition Mechanism Compared to Coumarins. *Journal of Medicinal Chemistry*, **2016**, 59, 462-73	8.3	62
622	Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 104-12	3.4	15
621	Polyamines and Carbonic Anhydrases. *Molecules*, **2016**, 21,	4.8	5
620	Biodegradation of 2-naphthalensulfonic acid polymers by white-rot fungi: Scale-up into non-sterile packed bed bioreactors. *Chemosphere*, **2016**, 164, 120-127	8.4	20
619	Plasmonic Particles that Hit Hypoxic Cells. *Advanced Functional Materials*, **2015**, 25, 316-323	15.6	34
618	Dipotassium-trioxohydroxytetrafluorotriborate, K[BOF][BOH], is a potent inhibitor of human carbonic anhydrases. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 341-4	5.6	23
617	A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 1828-40	3.4	103
616	Sulfonamide inhibition studies of the carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3550-5	2.9	28
615	Cloning, characterization and anion inhibition studies of a new carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4405-4409	3.4	25
614	Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 2368-76	3.4	34
613	Sulfonamide inhibition studies of the carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 1728-34	3.4	32
612	Development and ex vivo evaluation of 5-aminolevulinic acid-loaded niosomal formulations for topical photodynamic therapy. *International Journal of Pharmaceutics*, **2015**, 494, 258-63	6.5	23
611	Cyclodextrin complexation highly enhances efficacy of arylsulfonylureido benzenesulfonamide carbonic anhydrase inhibitors as a topical antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6223-7	3.4	9
610	Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX and XII). *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 586-91	5.6	105
609	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 689-721	5.6	79
608	6-Substituted 1,2-benzoxathiine-2,2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA. *Organic and Biomolecular Chemistry*, **2015**, 13, 77-80	3.9	30
607	Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 466-71	5.6	14
606	Benzenesulfonamides incorporating bulky aromatic/heterocyclic tails with potent carbonic anhydrase inhibitory activity. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 7751-64	3.4	16

605	Carbonic Anhydrases Possess Thioesterase Activity. *ACS Medicinal Chemistry Letters*, **2015**, 6, 292-5	4.3	28
604	The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 941-6	5.6	74
603	Anion inhibition study of the carbonic anhydrase (CahB1) from the cyanobacterium Coleofasciculus chthonoplastes (ex-Microcoleus chthonoplastes). *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1667-71	3.4	22
602	Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry* , **2014**, 22, 334-40	3.4	86
601	Sulfonamide inhibition studies of two carbonic anhydrases from the bacterial pathogen Legionella pneumophila. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 2939-46	3.4	41
600	Sulfonamide inhibition studies of the carbonic anhydrase from the diatom Thalassiosira weissflogii. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 275-9	2.9	47
599	Cloning, characterization and anion inhibition study of the class carbonic anhydrase (TweCA) from the marine diatom Thalassiosira weissflogii. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 531-7	3.4	56
598	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 4752-8	3.4	16
597	Furazan and furoxan sulfonamides are strong carbonic anhydrase inhibitors and potential antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3913-21	3.4	25
596	Synthesis of sulfonamides with effective inhibitory action against Porphyromonas gingivalis carbonic anhydrase. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4006-10	2.9	20
595	Anion inhibition study of the class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4402-4406	2.9	27
594	Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of three class carbonic anhydrases from Mycobacterium tuberculosis. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2014**, 29, 686-9	5.6	38
593	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the class (PgiCAb) versus the class (PgiCA) enzymes. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 4537-43	3.4	32
592	Anion inhibition studies of two new carbonic anhydrases from the bacterial pathogen Legionella pneumophila. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1127-32	2.9	44
591	Structural basis for the substrate specificity and the absence of dehalogenation activity in 2-chloromuconate cycloisomerase from Rhodococcus opacus 1CP. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2014**, 1844, 1541-9	4	2
590	Anion inhibition studies of two carbonic anhydrases from Lotus japonicus, LjCAA1 and LjCAA2. *Journal of Inorganic Biochemistry*, **2014**, 136, 67-72	4.2	15
589	Sulfonamide inhibition studies of the carbonic anhydrase from the oral pathogen Porphyromonas gingivalis. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 240-4	2.9	46
588	Biochemical properties of a new carbonic anhydrase from the human pathogenic bacterium, Vibrio cholerae. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2014**, 29, 23-7	5.6	85

587	Crystallization and preliminary X-ray crystallographic analysis of the small subunit of the heterodimeric laccase POXA3b from Pleurotus ostreatus. *Acta Crystallographica Section F, Structural Biology Communications*, **2014**, 70, 76-9	1.1	4
586	Sulfonamides and their isosters as carbonic anhydrase inhibitors. *Future Medicinal Chemistry*, **2014**, 6, 1149-65	4.1	133
585	Biochemical characterization of the β-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis, PgiCA. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2014**, 29, 532-7	5.6	62
584	A class of 4-sulfamoylphenyl-ε-aminoalkyl ethers with effective carbonic anhydrase inhibitory action and antiglaucoma effects. *Journal of Medicinal Chemistry*, **2014**, 57, 9673-86	8.3	44
583	Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups. *Journal of Medicinal Chemistry*, **2014**, 57, 9152-67	8.3	46
582	Inhibition studies of new ureido-substituted sulfonamides incorporating a GABA moiety against human carbonic anhydrase isoforms I-XIV. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 6768-75	3.4	21
581	Effect of carbon source on the degradation of 2-naphthalenesulfonic acid polymers mixture by Pleurotus ostreatus in petrochemical wastewater. *Process Biochemistry*, **2014**, 49, 2272-2278	4.8	15
580	Sulfonamide inhibition studies of the β-carbonic anhydrase from Drosophila melanogaster. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2797-801	2.9	10
579	Glaucoma and the applications of carbonic anhydrase inhibitors. *Sub-Cellular Biochemistry*, **2014**, 75, 349-59	5.5	86
578	Next-generation polyamine human carbonic anhydrase inhibitors **2014**, 68-81		
577	Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2013**, 28, 294-8	5.6	71
576	X-ray structures of 4-chlorocatechol 1,2-dioxygenase adducts with substituted catechols: new perspectives in the molecular basis of intradiol ring cleaving dioxygenases specificity. *Journal of Structural Biology*, **2013**, 181, 274-82	3.4	8
575	Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 3949-57	3.4	45
574	A class of sulfonamides with strong inhibitory action against the β-carbonic anhydrase from Trypanosoma cruzi. *Journal of Medicinal Chemistry*, **2013**, 56, 5773-81	8.3	51
573	Anion inhibition studies of a β-carbonic anhydrase from Clostridium perfringens. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6706-10	2.9	42
572	Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6759-63	2.9	37
571	Structural modulation of the biological activity of gold nanoparticles functionalized with a carbonic anhydrase inhibitor. *European Physical Journal E*, **2013**, 36, 48	1.5	9
570	Restoring catalytic activity to the human carbonic anhydrase (CA) related proteins VIII, X and XI affords isoforms with high catalytic efficiency and susceptibility to anion inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 256-60	2.9	37

569	The salicylate 1,2-dioxygenase as a model for a conventional gentisate 1,2-dioxygenase: crystal structures of the G106A mutant and its adducts with gentisate and salicylate. *FEBS Journal*, **2013**, 280, 1643-52	5.7	22
568	Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2013**, 28, 388-91	5.6	82
567	New selective carbonic anhydrase IX inhibitors: synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1451-64	3.4	49
566	Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. *Journal of Medicinal Chemistry*, **2013**, 56, 293-300	8.3	174
565	An □carbonic anhydrase from the thermophilic bacterium Sulphurihydrogenibium azorense is the fastest enzyme known for the CO2 hydration reaction. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1465-9	3.4	96
564	The extremo-□carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 1087-90	2.9	52
563	Antiobesity carbonic anhydrase inhibitors: a literature and patent review. *Expert Opinion on Therapeutic Patents*, **2013**, 23, 725-35	6.8	213
562	Inhibition of human carbonic anhydrase isoforms I-XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 6929-36	3.4	18
561	Kinetic and anion inhibition studies of a □carbonic anhydrase (FbiCA 1) from the C4 plant Flaveria bidentis. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 1626-30	2.9	33
560	Inhibition of tumor-associated human carbonic anhydrase isozymes IX and XII by a new class of substituted-phenylacetamido aromatic sulfonamides. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5228-32	3.4	19
559	A highly catalytically active □carbonic anhydrase from the pathogenic anaerobe Porphyromonas gingivalis and its inhibition profile with anions and small molecules. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 4067-71	2.9	58
558	The extremo-□carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium azorense is highly inhibited by sulfonamides. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 4521-5	3.4	60
557	Cloning, characterization, and sulfonamide and thiol inhibition studies of an □carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. *Journal of Medicinal Chemistry*, **2013**, 56, 1761-71	8.3	81
556	Structural effect of phenyl ring compared to thiadiazole based adamantyl-sulfonamides on carbonic anhydrase inhibition. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 2314-2318	3.4	19
555	Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012). *Expert Opinion on Therapeutic Patents*, **2013**, 23, 777-88	6.8	23
554	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1534-8	3.4	50
553	Secondary and tertiary sulfonamides: a patent review (2008 - 2012). *Expert Opinion on Therapeutic Patents*, **2013**, 23, 203-13	6.8	67
552	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 715-9	2.9	28

551	X-ray crystallographic and molecular docking studies on a unique chloromuconolactone dehalogenase from Rhodococcus opacus 1CP. *Journal of Structural Biology*, **2013**, 182, 44-50	3.4	2
550	Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three -class carbonic anhydrases from Mycobacterium tuberculosis. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2013**, 28, 384-7	5.6	71
549	Inhibition of the -class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2013**, 28, 392-6	5.6	68
548	Anion inhibition studies of the -carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 1636-8	2.9	50
547	Antiglaucoma carbonic anhydrase inhibitors: a patent review. *Expert Opinion on Therapeutic Patents* , **2013**, 23, 705-16	6.8	232
546	Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. *Journal of Medicinal Chemistry*, **2013**, 56, 4691-700	8.3	82
545	7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 4502-10	3.4	62
544	Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1564-9	3.4	43
543	Anion inhibition studies of the -carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 4472-6	3.4	45
542	X-ray structure of the first -extremo--carbonic anhydrase: a dimeric enzyme from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1. *Acta Crystallographica Section D: Biological Crystallography*, **2013**, 69, 1150-9		89
541	Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. *Cell Cycle*, **2013**, 12, 1791-801	4.7	119
540	Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2266-73	3.4	101
539	5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 267-70	2.9	54
538	Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 859-62	2.9	89
537	New chemotypes acting as isozyme-selective carbonic anhydrase inhibitors with low affinity for the offtarget cytosolic isoform II. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2182-5	2.9	46
536	Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3063-6	2.9	20
535	Inhibition of beta-carbonic anhydrases from the bacterial pathogen Brucella suis with inorganic anions. *Journal of Inorganic Biochemistry*, **2012**, 110, 36-9	4.2	27
534	Crystallization and preliminary X-ray crystallographic analysis of hydroquinone dioxygenase from Sphingomonas sp. TTNP3. *Acta Crystallographica Section F: Structural Biology Communications*, **2012** , 68, 588-90		3

533	Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit β and ζ carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms. *Journal of Medicinal Chemistry*, **2012**, 55, 9619-29	8.3	32
532	Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. *Journal of Medicinal Chemistry*, **2012**, 55, 5591-600	8.3	123
531	DNA cloning, characterization, and inhibition studies of an ε carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. *Journal of Medicinal Chemistry*, **2012**, 55, 10742-8	8.3	91
530	The generation of a 1-hydroxy-2-naphthoate 1,2-dioxygenase by single point mutations of salicylate 1,2-dioxygenase--rational design of mutants and the crystal structures of the A85H and W104Y variants. *Journal of Structural Biology*, **2012**, 180, 563-71	3.4	11
529	Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7142-5	2.9	60
528	Inhibition of β-class cytosolic human carbonic anhydrases I, II, IX and XII, and β-class fungal enzymes by carboxylic acids and their derivatives: new isoform-I selective nanomolar inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5801-6	2.9	29
527	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable ζ-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 6324-7	2.9	69
526	Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. *Chemical Communications*, **2012**, 48, 1868-70	5.8	149
525	Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. *Chemical Communications*, **2012**, 48, 8177-9	5.8	62
524	Serendipitous fragment-based drug discovery: ketogenic diet metabolites and statins effectively inhibit several carbonic anhydrases. *Chemical Communications*, **2012**, 48, 3551-3	5.8	22
523	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. *Journal of Medicinal Chemistry*, **2012**, 55, 3513-20	8.3	44
522	Heterocyclic urea derivatives and methods of use thereof (WO2010142978). *Expert Opinion on Therapeutic Patents*, **2012**, 22, 193-7	6.8	
521	Reaction intermediates and redox state changes in a blue laccase from Steccherinum ochraceum observed by crystallographic high/low X-ray dose experiments. *Journal of Inorganic Biochemistry*, **2012**, 111, 203-9	4.2	24
520	Crystal structures of salicylate 1,2-dioxygenase-substrates adducts: A step towards the comprehension of the structural basis for substrate selection in class III ring cleaving dioxygenases. *Journal of Structural Biology*, **2012**, 177, 431-8	3.4	24
519	Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4681-5	2.9	51
518	Anion inhibition studies of an ε carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5630-4	2.9	71
517	Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. *Journal of Medicinal Chemistry*, **2012**, 55, 1721-30	8.3	195
516	Enzymatic decolorization of spent textile dyeing baths composed by mixtures of synthetic dyes and additives. *Applied Microbiology and Biotechnology*, **2012**, 96, 395-405	5.7	11

515	Novel therapies for glaucoma: a patent review 2007 - 2011. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 79-88	6.8	104
514	Protein-protein interactions: inhibition of mammalian carbonic anhydrases I-XV by the murine inhibitor of carbonic anhydrase and other members of the transferrin family. *Journal of Medicinal Chemistry*, **2012**, 55, 5529-35	8.3	25
513	Sulfonamides: a patent review (2008 - 2012). *Expert Opinion on Therapeutic Patents*, **2012**, 22, 747-58	6.8	167
512	Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes. *Current Pharmaceutical Design*, **2012**, 18, 1407-13	3.3	14
511	Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. *Journal of Medicinal Chemistry*, **2011**, 54, 3977-81	8.3	65
510	Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. *Journal of Medicinal Chemistry*, **2011**, 54, 8271-7	8.3	201
509	Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. *Cancer Research*, **2011**, 71, 3364-76	10.1	563
508	Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. *Journal of Medicinal Chemistry*, **2011**, 54, 1896-902	8.3	391
507	Pyridinium derivatives of histamine are potent activators of cytosolic carbonic anhydrase isoforms I, II and VII. *Organic and Biomolecular Chemistry*, **2011**, 9, 2790-800	3.9	25
506	Carbonic anhydrase activators: gold nanoparticles coated with derivatized histamine, histidine, and carnosine show enhanced activatory effects on several mammalian isoforms. *Journal of Medicinal Chemistry*, **2011**, 54, 1170-7	8.3	43
505	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. *Radiotherapy and Oncology*, **2011**, 99, 424-31	5.3	144
504	Differential decolorization of textile dyes in mixtures and the joint effect of laccase and cellobiose dehydrogenase activities present in extracellular extracts from Funalia trogii. *Enzyme and Microbial Technology*, **2011**, 49, 465-71	3.8	27
503	Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4884-7	2.9	20
502	Synthesis of rhodamine B-benzenesulfonamide conjugates and their inhibitory activity against human □and bacterial/fungal □carbonic anhydrases. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5210-3	2.9	11
501	Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5892-6	2.9	7
500	A new □carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 1172-8	3.4	72
499	Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 3732-8	3.4	45
498	Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2. *Expert Opinion on Therapeutic Patents*, **2011**, 21, 803-6	6.8	

497	Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 243-8	3.4	69
496	Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 1381-9	3.4	89
495	Purification and inhibition studies with anions and sulfonamides of an β-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 1847-51	3.4	7
494	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 5023-30	3.4	45
493	An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2764-8	2.9	25
492	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 102-5	2.9	26
491	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. *Bioorganic and Medicinal Chemistry Letters* , **2011**, 21, 710-4	2.9	25
490	Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2521-6	2.9	28
489	Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII. *Bioorganic and Medicinal Chemistry Letters* , **2011**, 21, 2975-9	2.9	12
488	Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3216-21	2.9	42
487	Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3591-5	2.9	63
486	Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 3105-19	3.4	82
485	Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. *Current Pharmaceutical Design*, **2010**, 16, 3288-99	3.3	40
484	The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 850-4	8.3	110
483	Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. *Journal of Medicinal Chemistry*, **2010**, 53, 335-44	8.3	311
482	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. *Journal of Medicinal Chemistry*, **2010**, 53, 2277-85	8.3	97
481	Catechol 1,2-dioxygenase from the Gram-positive Rhodococcus opacus 1CP: quantitative structure/activity relationship and the crystal structures of native enzyme and catechols adducts. *Journal of Structural Biology*, **2010**, 170, 548-64	3.4	36
480	Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. *Chemical Communications*, **2010**, 46, 8371-3	5.8	180

479	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. *Journal of Medicinal Chemistry*, **2010**, 53, 5511-22	8.3	184
478	Carbonic anhydrase inhibitors: Gd(III) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. *New Journal of Chemistry*, **2010**, 34, 2139	3.6	5
477	The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. *Current Pharmaceutical Design*, **2010**, 16, 3300-9	3.3	70
476	3-phenyl-1H-indole-5-sulfonamides: structure-based drug design of a promising class of carbonic anhydrase inhibitors. *Current Pharmaceutical Design*, **2010**, 16, 3317-26	3.3	15
475	Carbonic anhydrase activators: activation of the beta-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 1034-7	3.4	18
474	Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 4873-8	3.4	57
473	Experimental and theoretical affinity studies of substituted phenols to chlorocatechol 1,2-dioxygenases: A step toward the comprehension of inhibitor/substrate binding to intradiol dioxygenases. *Journal of Molecular Catalysis B: Enzymatic*, **2010**, 64, 53-59		5
472	Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2178-82	2.9	48
471	Carbonic anhydrase inhibitors. The beta-carbonic anhydrases from the fungal pathogens Cryptococcus neoformans and Candida albicans are strongly inhibited by substituted-phenyl-1H-indole-5-sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2508-11	2.9	26
470	Design, solid-phase synthesis, and biological evaluation of novel 1,5-diarylpyrrole-3-carboxamides as carbonic anhydrase IX inhibitors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 7392-401	3.4	20
469	Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct--an inhibitor mimicking the sulfonamide and urea binding to the enzyme. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 474-8	2.9	74
468	Carbonic anhydrase activators: Activation of the beta-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1701-4	2.9	17
467	Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1548-50	2.9	45
466	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4376-81	2.9	66
465	Inhibition of the R1 fragment of the cadmium-containing zeta-class carbonic anhydrase from the diatom Thalassiosira weissflogii with anions. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4745-8	2.9	35
464	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5050-3	2.9	135
463	7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7255-8	2.9	143
462	Characterization of the first beta-class carbonic anhydrase from an arthropod (Drosophila melanogaster) and phylogenetic analysis of beta-class carbonic anhydrases in invertebrates. *BMC Biochemistry*, **2010**, 11, 28	4.8	57

461	Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 16233-8	11.5	399
460	Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2009**, 24, 499-505	5.6	18
459	Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. *Proteins: Structure, Function and Bioinformatics*, **2009**, 74, 164-75	4.2	90
458	Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates?. *Chemical Biology and Drug Design*, **2009**, 74, 317-21	2.9	62
457	Carbonic anhydrase inhibitors: inhibition studies of a coral secretory isoform with inorganic anions. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 650-3	2.9	27
456	Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2931-4	2.9	12
455	Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3430-3	2.9	11
454	Role of surfactants in optimizing fluorene assimilation and intermediate formation by Rhodococcus rhodochrous VKM B-2469. *Bioresource Technology*, **2009**, 100, 839-44	11	26
453	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 1214-21	3.4	53
452	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 1158-63	3.4	78
451	Carbonic anhydrase inhibitors. The nematode alpha-carbonic anhydrase of Caenorhabditis elegans CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3212-5	3.4	15
450	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3649-52	3.4	27
449	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 4503-9	3.4	51
448	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5054-8	3.4	29
447	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 4894-9	3.4	35
446	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the cytosolic isoforms I and II. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 7093-9	3.4	18
445	Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1155-8	2.9	13
444	A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1371-5	2.9	18

443	Carbonic anhydrase activators: activation of the beta-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1662-5	2.9	16
442	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1855-7	2.9	35
441	Carbonic anhydrase activators: activation of human isozymes I, II and IX with phenylsulfonylhydrazido l-histidine derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2440-3	2.9	21
440	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2642-5	2.9	42
439	Carbonic anhydrase inhibitors. Phenacetyl-, pyridylacetyl- and thienylacetyl-substituted aromatic sulfonamides act as potent and selective isoform VII inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3170-3	2.9	33
438	The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4102-6	2.9	64
437	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4929-32	2.9	27
436	The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5825-8	2.9	73
435	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference. *Journal of Medicinal Chemistry*, **2009**, 52, 322-8	8.3	49
434	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. *Journal of Medicinal Chemistry*, **2009**, 52, 646-54	8.3	23
433	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2009**, 24 Suppl 1, 1-39	5.6	153
432	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. *Journal of Medicinal Chemistry*, **2009**, 52, 3116-20	8.3	98
431	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. *Journal of Medicinal Chemistry*, **2009**, 52, 2226-32	8.3	85
430	Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. *Journal of Medicinal Chemistry*, **2009**, 52, 4063-7	8.3	75
429	Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. *Journal of the American Chemical Society*, **2009**, 131, 3057-62	16.4	400
428	Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with anions. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2009**, 24, 70-6	5.6	32
427	QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2009**, 24, 337-49	5.6	11
426	Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. *Radiotherapy and Oncology*, **2009**, 92, 423-8	5.3	173

425	Inhibition of carbonic anhydrase IX: a new strategy against cancer. *Anti-Cancer Agents in Medicinal Chemistry*, **2009**, 9, 693-702	2.2	31
424	Laccase isoforms with unusual properties from the basidiomycete Steccherinum ochraceum strain 1833. *Journal of Applied Microbiology*, **2008**, 105, 2065-75	4.7	29
423	External pH influences the transcriptional profile of the carbonic anhydrase, CAH-4b in Caenorhabditis elegans. *Molecular and Biochemical Parasitology*, **2008**, 161, 140-9	1.9	25
422	Salicylate 1,2-dioxygenase from Pseudaminobacter salicylatoxidans: crystal structure of a peculiar ring-cleaving dioxygenase. *Journal of Molecular Biology*, **2008**, 380, 856-68	6.5	36
421	Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications?. *Organic and Biomolecular Chemistry*, **2008**, 6, 2499-506	3.9	74
420	Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. *Journal of Biological Chemistry*, **2008**, 283, 27799-27809	5.4	224
419	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. *Journal of Medicinal Chemistry*, **2008**, 51, 3230-7	8.3	46
418	Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. *Journal of the American Chemical Society*, **2008**, 130, 16130-1	16.4	99
417	The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. *Current Pharmaceutical Design*, **2008**, 14, 649-54	3.3	78
416	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with some 1,3,4-oxadiazole- and 1,2,4-triazole-thiols. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2008**, 23, 101-7	5.6	19
415	Carbonic anhydrase activation and the drug design. *Current Pharmaceutical Design*, **2008**, 14, 708-15	3.3	73
414	Design of zinc binding functions for carbonic anhydrase inhibitors. *Current Pharmaceutical Design*, **2008**, 14, 615-21	3.3	69
413	Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents. *Anti-Infective Agents in Medicinal Chemistry*, **2008**, 7, 169-179		11
412	Cloning, polymorphism, and inhibition of beta-carbonic anhydrase of Helicobacter pylori. *Journal of Gastroenterology*, **2008**, 43, 849-57	6.9	40
411	Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. *Medicinal Research Reviews*, **2008**, 28, 445-63	14.4	192
410	Carbonic anhydrase inhibitors: binding of indanesulfonamides to the human isoform II. *ChemMedChem*, **2008**, 3, 473-7	3.7	10
409	Carbonic anhydrase inhibitors: design of membrane-impermeant copper(II) complexes of DTPA-, DOTA-, and TETA-tailed sulfonamides targeting the tumor-associated transmembrane isoform IX. *ChemMedChem*, **2008**, 3, 1780-8	3.7	28
408	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. *European Journal of Medicinal Chemistry*, **2008**, 43, 2853-60	6.8	19

407	Fungal laccase, cellobiose dehydrogenase, and chemical mediators: combined actions for the decolorization of different classes of textile dyes. *Bioresource Technology*, **2008**, 99, 7003-10	11	66
406	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 3933-40	3.4	27
405	Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 3530-6	3.4	44
404	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7424-8	3.4	114
403	Carbonic anhydrase activators: kinetic and X-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-XIV. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8373-8	3.4	60
402	Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 9113-20	3.4	21
401	Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 152-8	2.9	43
400	Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 999-1005	2.9	20
399	Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1583-7	2.9	170
398	Carbonic anhydrase inhibitors: the very weak inhibitors dithiothreitol, beta-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1898-903	2.9	6
397	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2567-73	2.9	59
396	Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors?. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3938-41	2.9	35
395	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4303-7	2.9	29
394	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4282-6	2.9	9
393	Carbonic anhydrase inhibitors: inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with simple anions. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5066-70	2.9	90
392	Carbonic anhydrase activators: activation of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 6194-8	2.9	33
391	Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 6332-5	2.9	18
390	Combined action of a bacterial monooxygenase and a fungal laccase for the biodegradation of mono- and poly-aromatic hydrocarbons. *Bioresource Technology*, **2008**, 99, 8353-9	11	15

389	Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 836-41	2.9	35
388	Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2267-71	2.9	88
387	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2669-74	2.9	30
386	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3593-6	2.9	56
385	Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3475-80	2.9	14
384	Crystal structure of the blue multicopper oxidase from the white-rot fungus Trametes trogii complexed with p-toluate. *Inorganica Chimica Acta*, **2008**, 361, 4129-4137	2.7	83
383	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. *Journal of Medicinal Chemistry*, **2007**, 50, 381-8	8.3	80
382	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2298-311	3.4	43
381	Carbonic anhydrase activators: the first activation study of the human secretory isoform VI with amino acids and amines. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 5351-7	3.4	42
380	Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4152-8	3.4	34
379	Carbonic anhydrases as targets for medicinal chemistry. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4336-50	3.4	462
378	Carbonic anhydrase inhibitors: the inhibition profiles of the human mitochondrial isoforms VA and VB with anions are very different. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6742-7	3.4	16
377	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 7229-36	3.4	90
376	Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1336-40	2.9	41
375	Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1726-31	2.9	35
374	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1538-43	2.9	27
373	Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1532-7	2.9	33
372	Carbonic anhydrase inhibitors: the X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2795-801	2.9	14

371	Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2685-91	2.9	42
370	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3585-94	2.9	146
369	Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 4107-12	2.9	45
368	Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 4866-72	2.9	34
367	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5086-90	2.9	38
366	Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2210-5	2.9	45
365	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 4201-7	2.9	45
364	Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5096-100	2.9	24
363	Crystal structure of a blue laccase from Lentinus tigrinus: evidences for intermediates in the molecular oxygen reductive splitting by multicopper oxidases. *BMC Structural Biology*, **2007**, 7, 60	2.7	91
362	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 628-35	2.9	82
361	Carbonic anhydrase inhibitors. Inhibition studies of the human secretory isoform VI with anions. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1037-42	2.9	32
360	Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. *Current Medicinal Chemistry*, **2007**, 14, 2734-48	4.3	115
359	The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. *Current Topics in Medicinal Chemistry*, **2007**, 7, 849-54	3	49
358	Metal binding functions in the design of carbonic anhydrase inhibitors. *Current Topics in Medicinal Chemistry*, **2007**, 7, 835-48	3	22
357	An update in the development of HIV entry inhibitors. *Current Topics in Medicinal Chemistry*, **2007**, 7, 1273-89	3	56
356	ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. *Chemical Communications*, **2007**, 156-8	5.8	126
355	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. *Radiotherapy and Oncology*, **2007**, 83, 367-73	5.3	138
354	Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 437-42	2.9	89

353	Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3139-43	2.9	26
352	Carbonic anhydrase activators: activation of isozyme XIII with amino acids and amines. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3955-9	2.9	45
351	Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 6204-8	2.9	31
350	Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. *Chemistry - A European Journal*, **2006**, 12, 7057-66	4.8	122
349	Therapeutic potential of sulfamides as enzyme inhibitors. *Medicinal Research Reviews*, **2006**, 26, 767-92	14.4	153
348	Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. *Current Pharmaceutical Design*, **2006**, 12, 3459-65	3.3	50
347	New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 921-36	3.2	70
346	The sulfamide motif in the design of enzyme inhibitors. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 27-47	6.8	65
345	Inhibitors of HIV-1 protease: 10 years after. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 1067-1091	6.8	18
344	Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. *Journal of Medicinal Chemistry*, **2006**, 49, 3019-27	8.3	116
343	Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2006**, 21, 351-9	5.6	7
342	Carbonic anhydrase inhibitors. N-cyanomethylsulfonamides--a new zinc binding group in the design of inhibitors targeting cytosolic and membrane-anchored isoforms. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2006**, 21, 477-81	5.6	2
341	Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2006**, 21, 563-8	5.6	16
340	3D QSAR selectivity analyses of carbonic anhydrase inhibitors: insights for the design of isozyme selective inhibitors. *Journal of Chemical Information and Modeling*, **2006**, 46, 2737-60	6.1	28
339	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. *Journal of Medicinal Chemistry*, **2006**, 49, 5544-51	8.3	93
338	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. *Journal of Medicinal Chemistry*, **2006**, 49, 7024-31	8.3	142
337	Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. *Journal of the American Chemical Society*, **2006**, 128, 8329-35	16.4	186
336	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. *Journal of Medicinal Chemistry*, **2006**, 49, 2117-26	8.3	137

335	Crystal structure of 3-chlorocatechol 1,2-dioxygenase key enzyme of a new modified ortho-pathway from the Gram-positive Rhodococcus opacus 1CP grown on 2-chlorophenol. *Journal of Molecular Biology*, **2006**, 360, 788-99	6.5	33
334	Carbonic anhydrase inhibitors and activators and their use in therapy. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 1627-1664	6.8	143
333	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 2182-8	2.9	36
332	N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4316-20	2.9	34
331	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4846-51	2.9	46
330	Carbonic anhydrase inhibitors: transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 2418-27	3.4	16
329	Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5152-6	2.9	74
328	Crystal structure of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E, a key enzyme involved in polychlorinated aromatics biodegradation. *Journal of Biological Chemistry*, **2005** , 280, 21144-54	5.4	38
327	Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 211-7	5.6	16
326	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. *Journal of Medicinal Chemistry*, **2005**, 48, 4834-41	8.3	192
325	Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. *Journal of Medicinal Chemistry*, **2005**, 48, 5721-7	8.3	150
324	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 7860-6	8.3	161
323	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. *Journal of Medicinal Chemistry*, **2005**, 48, 2121-5	8.3	69
322	Evaluation of an FIA Operated Amperometric Bacterial Biosensor, Based on Pseudomonas Putida F1 for the Detection of Benzene, Toluene, Ethylbenzene, and Xylenes (BTEX). *Analytical Letters*, **2005**, 38, 1531-1547	2.2	13
321	Metal binding and antibacterial activity of ciprofloxacin complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 303-7	5.6	130
320	Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 483-9	3.4	75
319	Carbonic anhydrase inhibitors: inhibition of the human transmembrane isozyme XIV with a library of aromatic/heterocyclic sulfonamides. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6089-93	3.4	20
318	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 567-71	2.9	30

317	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 573-8	2.9	60
316	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 579-84	2.9	41
315	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1149-54	2.9	29
314	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 971-6	2.9	128
313	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1683-6	2.9	23
312	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1909-13	2.9	18
311	Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1937-42	2.9	38
310	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides--a new zinc-binding function in the design of inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 2353-8	2.9	43
309	Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 2315-20	2.9	166
308	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3096-101	2.9	106
307	Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3302-6	2.9	49
306	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 4862-6	2.9	25
305	Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 5136-41	2.9	91
304	Carbonic anhydrase inhibitors. Inhibition of red blood cell ostrich (Struthio camelus) carbonic anhydrase with a series of aromatic and heterocyclic sulfonamides. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 383-7	5.6	5
303	Sulfamates and their therapeutic potential. *Medicinal Research Reviews*, **2005**, 25, 186-228	14.4	169
302	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 367-72	2.9	48
301	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 963-9	2.9	199
300	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 2359-64	2.9	23

299	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 2347-52	2.9	64
298	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3102-8	2.9	129
297	Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 4872-6	2.9	32
296	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3821-7	2.9	25
295	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3828-33	2.9	125
294	Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 5192-6	2.9	19
293	Crystallization and preliminary structure analysis of the blue laccase from the ligninolytic fungus Panus tigrinus. *Acta Crystallographica Section F: Structural Biology Communications*, **2005**, 61, 205-7		5
292	Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. *Current Pharmaceutical Design*, **2005**, 11, 1805-43	3.3	199
291	Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. *Journal of Biological Chemistry*, **2004**, 279, 2719-27	5.4	187
290	COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 625-32	3.2	116
289	Protein tyrosine kinase inhibitors as anticancer agents. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 35-53	6.8	29
288	Designing of Novel Carbonic Anhydrase Inhibitors and Activators. *Current Medicinal Chemistry Cardiovascular and Hematological Agents*, **2004**, 2, 49-68		119
287	Antiviral sulfonamide derivatives. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 189-200	3.2	84
286	Crystal structure of 4-chlorocatechol 1,2-dioxygenase from the chlorophenol-utilizing gram-positive Rhodococcus opacus 1CP. *Journal of Biological Chemistry*, **2004**, 279, 27646-55	5.4	44
285	Carbonic anhydrase inhibitors: Schiff bases of aromatic and heterocyclic sulfonamides and their metal complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 263-7	5.6	55
284	Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 217-23	2.9	235
283	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 231-4	2.9	137
282	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 2351-6	2.9	45

281	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5435-9	2.9	42
280	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5775-80	2.9	45
279	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5763-7	2.9	23
278	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 6001-6	2.9	77
277	Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 2717-26	3.4	82
276	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5427-33	2.9	90
275	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 225-9	2.9	64
274	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 337-41	2.9	62
273	Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 869-73	2.9	140
272	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 2357-61	2.9	46
271	Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3283-90	2.9	69
270	Carbonic anhydrase inhibitors. Inhibition of the zinc and cobalt gamma-class enzyme from the archaeon Methanosarcina thermophila with anions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3327-31	2.9	14
269	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3757-62	2.9	36
268	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4563-7	2.9	47
267	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5703-7	2.9	15
266	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5781-6	2.9	25
265	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5769-73	2.9	26
264	Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 269-73	5.6	31

263	Carbonic anhydrase inhibitors: aliphatic N-phosphorylated sulfamates--a novel zinc-anchoring group leading to nanomolar inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 275-8	5.6	8
262	Therapeutic applications of sulfamates. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 1273-1308	6.8	29
261	Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 287-91	5.6	8
260	Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. *Journal of Medicinal Chemistry*, **2004**, 47, 2337-47	8.3	145
259	Carbonic anhydrase inhibitors. Inhibition of the zinc and cobalt $gamma;-class enzyme from the archaeon Methanosarcina thermophila with anions. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3327-3331	2.9	57
258	Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. *Journal of Medicinal Chemistry*, **2004**, 47, 550-7	8.3	381
257	Metalloantibiotics: synthesis and antibacterial activity of cobalt(II), copper(II), nickel(II) and zinc(II) complexes of kefzol. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 79-84	5.6	135
256	Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity. *Journal of Medicinal Chemistry*, **2004**, 47, 2796-804	8.3	32
255	Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. *Journal of Medicinal Chemistry*, **2004**, 47, 1272-9	8.3	135
254	Modulation of carbonic anhydrase activity and its applications in therapy. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 667-702	6.8	148
253	Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. *Journal of Medicinal Chemistry*, **2004**, 47, 5224-9	8.3	46
252	Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. *FEBS Letters*, **2004**, 577, 439-45	3.8	556
251	Carbonic Anhydrase Inhibitors in Dermatology **2004**, 303-315		12
250	Carbonic Anhydrase Activators **2004**, 317-352		13
249	New advances in HIV entry inhibitors development. *Current Drug Targets Infectious Disorders*, **2004**, 4, 339-55		31
248	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 333-8	5.6	21
247	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 303-8	5.6	47
246	Anticancer and antiviral sulfonamides. *Current Medicinal Chemistry*, **2003**, 10, 925-53	4.3	557

245	Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. *Biochemistry*, **2003**, 42, 9013-21	3.2	13
244	Carbonic anhydrase inhibitors. *Medicinal Research Reviews*, **2003**, 23, 146-89	14.4	1062
243	Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. *Medicinal Research Reviews*, **2003**, 23, 535-58	14.4	320
242	Density functional characterization of the chemoselective oxidation of catechol by using molecular oxygen: thermodynamics of the reaction between [(triphos)Ir(dtbc)]+ and O2. *Chemistry - A European Journal*, **2003**, 9, 3015-23	4.8	6
241	Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 837-40	2.9	73
240	Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 841-5	2.9	209
239	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2765-8	2.9	21
238	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide-two heads are better than one?. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2759-63	2.9	33
237	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2867-73	2.9	30
236	Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2857-61	2.9	44
235	Hydroxyurea is a carbonic anhydrase inhibitor. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2241-6	3.4	36
234	Preliminary crystallographic analysis of 3-chlorocatechol 1,2-dioxygenase of a new modified ortho-pathway from the Gram-positive Rhodococcus opacus 1CP grown on 2-chlorophenol. *Acta Crystallographica Section D: Biological Crystallography*, **2003**, 59, 188-90		4
233	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 1005-9	2.9	176
232	Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2227-39	3.4	23
231	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. *Journal of Medicinal Chemistry*, **2003**, 46, 2187-96	8.3	133
230	Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 259-63	5.6	130
229	Synthesis of Biologically Active Co(II), Cu(II), Ni(II) and Zn(II) Complexes of Symmetrically 1,1?-Disubstituted Ferrocene-Derived Compounds. *Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry*, **2003**, 33, 241-257		34
228	Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. *Journal of Medicinal Chemistry*, **2003**, 46, 5471-7	8.3	74

227	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. *Journal of Medicinal Chemistry*, **2003**, 46, 2197-204	8.3	134
226	Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 233-42	5.6	13
225	Carbonic anhydrase inhibitors. inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 403-6	5.6	53
224	Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs. *Environmental Health Perspectives*, **2002**, 110 Suppl 5, 801-6	8.4	29
223	Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents. *Journal of Pharmaceutical Sciences*, **2002**, 91, 2211-9	3.9	13
222	Bacterial protease inhibitors. *Medicinal Research Reviews*, **2002**, 22, 329-72	14.4	128
221	Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1177-80	2.9	60
220	4-Chlorocatechol 1,2-dioxygenase from the chlorophenol-utilizing Gram-positive Rhodococcus opacus 1CP: crystallization and preliminary crystallographic analysis. *Acta Crystallographica Section D: Biological Crystallography*, **2002**, 58, 1074-6		3
219	Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1551-7	2.9	18
218	Crystal analysis of aromatic sulfonamide binding to native and (Zn)2 adduct of human carbonic anhydrase I Michigan 1. *Inorganica Chimica Acta*, **2002**, 339, 135-144	2.7	9
217	Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. *Journal of Medicinal Chemistry*, **2002**, 45, 312-20	8.3	129
216	Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line. *Pharmaceutical Research*, **2002**, 19, 1337-44	4.5	23
215	Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2667-72	2.9	22
214	Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 1307-1327	6.8	46
213	Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 69-76	5.6	39
212	Antibacterial Co(II), Cu(II), Ni(II) and Zn(II) complexes of thiadiazole derived furanyl, thiophenyl and pyrrolyl Schiff bases. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 117-22	5.6	61
211	Antibacterial cobalt(II), nickel(II) and zinc(II) complexes of nicotinic acid-derived Schiff-bases. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 101-6	5.6	28
210	Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs. *Current Medicinal Chemistry*, **2002**, 9, 1167-85	4.3	54

209	Sulfonamides and sulfonylated derivatives as anticancer agents. *Current Cancer Drug Targets*, **2002**, 2, 55-75	2.8	209
208	Transition metal acetylsalicylates and their anti-inflammatory activity. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 87-91	5.6	35
207	Therapeutic applications of serine protease inhibitors. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 1181-1214	6.8	23
206	Crystal structure of a zinc-activated variant of human carbonic anhydrase I, CA I Michigan 1: evidence for a second zinc binding site involving arginine coordination. *Biochemistry*, **2002**, 41, 6237-44	3.2	42
205	Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. *Journal of Medicinal Chemistry*, **2002**, 45, 3583-7	8.3	144
204	Nonionic Micelles Promote Whole Cell Bioconversion of Aromatic Substrates in an Aqueous Environment. *Langmuir*, **2002**, 18, 6015-6020	4	7
203	Unsymmetrical 1,1′-disubstituted ferrocenes: synthesis of Co(ii), Cu(ii), Ni(ii) and Zn(ii) chelates of ferrocenyl -1-thiadiazolo-1′-tetrazole, -1-thiadiazolo-1′-triazole and -1-tetrazolo-1′-triazole with antimicrobial properties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 261-6	5.6	115
202	Carbonic anhydrase inhibitors with strong topical antiglaucoma properties incorporating a 4-(2-aminopyrimidin-4-yl-amino)-benzenesulfonamide scaffold. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 9-18	5.6	11
201	Carbonic anhydrase inhibitors: synthesis of water soluble sulfonamides incorporating a 4-sulfamoylphenylmethylthiourea scaffold, with potent intraocular pressure lowering properties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 333-43	5.6	31
200	Applications of carbonic anhydrase inhibitors and activators in therapy. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 217-242	6.8	228
199	Carbonic anhydrase activators: design of high affinity isozymes I, II, and IV activators, incorporating tri-/tetrasubstituted-pyridinium-azole moieties. *Journal of Medicinal Chemistry*, **2002**, 45, 504-10	8.3	68
198	Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold. *Journal of Medicinal Chemistry*, **2002**, 45, 284-91	8.3	60
197	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. *Journal of Medicinal Chemistry*, **2002**, 45, 1466-76	8.3	127
196	Antibacterial Schiff bases of oxalyl-hydrazine/diamide incorporating pyrrolyl and salicylyl moieties and of their zinc(II) complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 1-7	5.6	78
195	Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 575-82	2.9	106
194	Antimycobacterial activity of 9-sulfonylated/sulfenylated-6-mercaptopurine derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1675-8	2.9	45
193	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1787-91	2.9	52
192	Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 703-14	3.4	225

191	Efficient polycyclic aromatic hydrocarbons dihydroxylation in direct micellar systems. *Biotechnology and Bioengineering*, **2001**, 74, 240-8	4.9	17
190	Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type. *Journal of Medicinal Chemistry*, **2001**, 44, 2253-8	8.3	34
189	Carbonic anhydrase inhibitors: allylsulfonamide, styrene sulfonamide, N-allyl sulfonamides and some of their Si, Ge, and B derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 475-89		9
188	Carbonic anhydrase inhibitors: metal complexes of a sulfanilamide derived Schiff base and their interaction with isozymes I, II and IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 499-505		18
187	Agents that target cysteine residues of biomolecules and their therapeutic potential. *Expert Opinion on Therapeutic Patents*, **2001**, 11, 765-787	6.8	22
186	Carbonic Anhydrase Inhibitors. *Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents*, **2001**, 1, 61-97		167
185	Carbonic anhydrase inhibitors, interaction of boron derivatives with isozymes I and II: a new binding site for hydrophobic inhibitors at the entrance of the active site as shown by docking studies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 125-33		12
184	Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. *Expert Opinion on Therapeutic Patents*, **2001**, 11, 1245-1252	6.8	21
183	Arylsulfonyl-N,N-dialkyl-dithiocarbamates as tumor cell growth inhibitors: novel agents targeting beta-tubulin?. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 55-63		9
182	Protease inhibitors, part 13: Specific, weakly basic thrombin inhibitors incorporating sulfonyl dicyandiamide moieties in their structure. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 1-13		3
181	Carbonic anhydrase inhibitors: synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5-norbornene-endo-3-carboxy-2-carboxamido moieties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 113-23		8
180	Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. *Expert Opinion on Therapeutic Patents*, **2001**, 11, 221-259	6.8	99
179	Antimycobacterial activity of 3,4-dichlorophenyl-ureas, N,N-diphenyl-ureas and related derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 425-32		14
178	Carbonic Anhydrase Activity Modulators: Synthesis of Inhibitors and Activators Incorporating 2-substituted-thiazol-4-yl-methyl Scaffolds. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 351-358		4
177	Carbonic anhydrase activators: synthesis of high affinity isozymes I, II and IV activators, derivatives of 4-(arylsulfonylureido-amino acyl)ethyl-1H-imidazole. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 471-86		13
176	Protease inhibitors: synthesis of clostridium histolyticum collagenase inhibitors incorporating sulfonyl-L-alanine hydroxamate moieties. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 499-502	2.9	24
175	Carbonic anhydrase inhibitors: topical sulfonamide antiglaucoma agents incorporating secondary amine moieties. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 673-6	2.9	56
174	Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 1117-20	2.9	33

173	Arylsulfonyl-N,N-diethyl-dithiocarbamates: a novel class of antitumor agents. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 1887-91	2.9	70
172	Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 2145-55	3.4	61
171	Protease inhibitors. Part 8: synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated L-alanine hydroxamate moieties. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 637-45	3.4	25
170	Protease inhibitors - part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase. *European Journal of Medicinal Chemistry*, **2000**, 35, 299-307	6.8	28
169	Carbonic anhydrase inhibitors - part 78(#). Synthesis of water-soluble sulfonamides incorporating beta-alanyl moieties, possessing long lasting-intraocular pressure lowering properties via the topical route. *European Journal of Medicinal Chemistry*, **2000**, 35, 309-21	6.8	11
168	Direct micellar systems as a tool to improve the efficiency of aromatic substrate conversion for fine chemicals production. *Journal of Inorganic Biochemistry*, **2000**, 79, 103-8	4.2	9
167	Carbonic anhydrase activators - part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties. *European Journal of Medicinal Chemistry*, **2000**, 35, 31-9	6.8	27
166	Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?. *European Journal of Medicinal Chemistry*, **2000**, 35, 867-74	6.8	86
165	Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-beta-alanine hydroxamate moieties. *European Journal of Pharmaceutical Sciences*, **2000**, 11, 69-79	5.1	15
164	Antifungal activity of silver and zinc complexes of sulfadrug derivatives incorporating arylsulfonylureido moieties. *European Journal of Pharmaceutical Sciences*, **2000**, 11, 99-107	5.1	40
163	4-toluenesulfonylureido derivatives of amines, amino acids and dipeptides: a novel class of potential antitumor agents. *European Journal of Pharmaceutical Sciences*, **2000**, 11, 325-32	5.1	30
162	Carbonic anhydrase activators. Part 24. High affinity isozymes I, II and IV activators, derivatives of 4-(4-chlorophenylsulfonylureido-amino acyl)ethyl-1H-imidazole. *European Journal of Pharmaceutical Sciences*, **2000**, 10, 29-41	5.1	32
161	Protease inhibitors. Part 7. Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of L-valine hydroxamate. *European Journal of Pharmaceutical Sciences*, **2000**, 10, 67-76	5.1	26
160	Purification and catalytic properties of two catechol 1,2-dioxygenase isozymes from benzoate-grown cells of Acinetobacter radioresistens. *The Protein Journal*, **2000**, 19, 709-16		39
159	Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic X-ray diffraction. *Biochemistry*, **2000**, 39, 12391-7	3.2	42
158	Carbonic anhydrase inhibitors. Part 91. Metal complexes of heterocyclic sulfonamides as potential pharmacological agents in the treatment of gastric Acid secretion imbalances. *Metal-Based Drugs*, **2000**, 7, 57-62		15
157	The antifungal activity of sulfonylated/carboxylated derivatives of dibenzo-1,4-dioxine-2-acetyloxime may be due to inhibition of lanosterol-14alpha-demethylase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 557-69		3
156	Antifungal activity of Ag(I) and Zn(II) complexes of aminobenzolamide (5-sulfanilylamido-1,3,4-thiadiazole-2-sulfonamide) derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 517-31		24

155	Carbonic anhydrase inhibitors: synthesis of Schiff bases of hydroxybenzaldehydes with aromatic sulfonamides and their reactions with arylsulfonyl isocyanates. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 533-46		21
154	Activation of carbonic anhydrase isozymes. *Exs*, **2000**, 197-219		18
153	Protease inhibitors: Part 4. Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 335-56		2
152	Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. *Journal of Medicinal Chemistry*, **2000**, 43, 1858-65	8.3	56
151	Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 597-610		55
150	Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. *Journal of Medicinal Chemistry*, **2000**,	8.3	202
149	Protease inhibitors: Synthesis of L-alanine hydroxamate sulfonylated derivatives as inhibitors of clostridium histolyticum collagenase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 111-28		10
148	Carbonic anhydrase inhibitors; phosphoryl-sulfonamides--a new class of high affinity inhibitors of isozymes I and II. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 297-310		8
147	Protease inhibitors. Part 2. Weakly basic thrombin inhibitors incorporating sulfonyl-aminoguanidine moieties as S1 anchoring groups: synthesis and structure-activity correlations. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 235-64		4
146	Carbonic anhydrase activators: synthesis of high affinity isozymes I, II and IV activators, derivatives of 4-(4-tosylureido-amino acyl)ethyl-1H-imidazole (histamine derivatives). *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 139-61		28
145	Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 381-401		39
144	Density functional description of the early stages of the dioxygenation of [(MeC(CH2PPh2)3)M(catecholate)]+ complexes [M = Co(III), Ir(III)]: toward a rationalization of the catalytic mechanism of ring-opening dioxygenases. *Inorganic Chemistry*, **2000**, 39, 1418-25	5.1	8
143	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV by sulfamide and sulfamic acid derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2000**, 15, 443-53		28
142	Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1. *Journal of Medicinal Chemistry*, **2000**, 43, 1793-806	8.3	29
141	Carbonic anhydrase inhibitors and their therapeutic potential. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 575-600	6.8	432
140	Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. *Journal of Medicinal Chemistry*, **2000**, 43, 292-300	8.3	138
139	Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects. *Journal of Medicinal Chemistry*, **2000**, 43, 4884-92	8.3	137
138	Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. *Journal of Medicinal Chemistry*, **2000**, 43, 4542-51	8.3	128

137	Carbonic Anhydrase Inhibitors Part 72 Synthesis and Antiglaucoma Properties of Metal Complexes of p-Fluorobenzolamide. *Metal-Based Drugs*, **1999**, 6, 67-73		9
136	Functionalized Derivatives of Benzo-Crown Ethers. Part 4. Antifungal Macrocyclic Supramolecular Complexes of Transition Metal Ions Acting as Lanosterol-14-alpha-Demethylase Ihibitors. *Metal-Based Drugs*, **1999**, 6, 101-10		5
135	Carbonic Anhydrase Inhibitors. Synthesis of Topically Effective Intraocular Pressure Lowering Agents Derived from 5-(Amino-Alkylcarboxamido)-1,3,4-Thia-Diazole-2-Sulfonamide. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 15, 23-46		35
134	INHIBITION OF CARBONIC ANHYDRASE ISOZYMES I, II AND IV WITH ARSINOLIPIDS. *Main Group Metal Chemistry*, **1999**, 22,	1.6	3
133	Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2043-8	2.9	31
132	Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring?. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 2397-406	3.4	148
131	Carbonic anhydrase activators: amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 2915-23	3.4	25
130	Carbonic anhydrase inhibitors part 70. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering agents derived from nicotinic acid and aromatic/heterocyclic sulfonamides. *European Journal of Medicinal Chemistry*, **1999**, 34, 799-808	6.8	11
129	Crystallization and preliminary crystallographic analysis of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E: a novel dioxygenase involved in the biodegradation of polychlorinated aromatic compounds. *Acta Crystallographica Section D: Biological Crystallography*, **1999**, 55, 901-3		10
128	Carbonic anhydrase inhibitors. Part 60(#). The topical intraocular pressure-lowering properties of metal complexes of a heterocyclic sulfonamide: influence of the metal ion upon biological activity. *European Journal of Medicinal Chemistry*, **1999**, 34, 585-95	6.8	11
127	Protease inhibitors - Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site. *European Journal of Medicinal Chemistry*, **1999**, 34, 939-952	6.8	11
126	Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?. *Journal of Medicinal Chemistry*, **1999**, 42, 2641-50	8.3	250
125	Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction?. *Journal of Biological Inorganic Chemistry*, **1999**, 4, 528-36	3.7	52
124	Carbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. *European Journal of Pharmaceutical Sciences*, **1999**, 8, 317-28	5.1	47
123	Carbonic anhydrase inhibitors. Part 79. Synthesis of topically acting sulfonamides incorporating GABA moieties in their molecule, with long-lasting intraocular pressure-lowering properties. *European Journal of Pharmaceutical Sciences*, **1999**, 9, 185-99	5.1	15
122	Characterization of the biological conversion of naphthalene to (+)-cis-(1R,2S)-dihydroxy-1,2-dihydronaphthalene in direct micellar systems. *Journal of Molecular Catalysis B: Enzymatic*, **1999**, 7, 263-272		7
121	Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. *Journal of Medicinal Chemistry*, **1999**, 42, 3690-700	8.3	146
120	Carbonic anhydrase inhibitors. Water-soluble, topically effective intraocular pressure lowering agents derived from isonicotinic acid and aromatic/heterocyclic sulfonamides: is the tail more important than the ring?. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 14, 457-74		28

119	Carbonic anhydrase inhibitors. Arylsulfonylureido- and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 14, 343-63		49
118	Carbonic anhydrase inhibitors. Schiff bases of some aromatic sulfonamides and their metal complexes: towards more selective inhibitors of carbonic anhydrase isozyme IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 14, 407-23		26
117	Carbonic anhydrase inhibitors: N-cyanosulfonamides, a new class of high affinity isozyme II and IV inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 14, 289-306		16
116	A ternary complex of carbonic anhydrase: X-ray crystallographic structure of the adduct of human carbonic anhydrase II with the activator phenylalanine and the inhibitor azide. *Inorganica Chimica Acta*, **1998**, 275-276, 295-300	2.7	25
115	Carbonic anhydrase inhibitors - Part 49: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. *European Journal of Medicinal Chemistry*, **1998**, 33, 83-93	6.8	139
114	Quantitative structure/activity relationship for the rate of conversion of C4-substituted catechols by catechol-1,2-dioxygenase from Pseudomonas putida (arvilla) C1. *FEBS Journal*, **1998**, 257, 92-100		16
113	Carbonic anhydrase inhibitors Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV. *European Journal of Medicinal Chemistry*, **1998**, 33, 577-594	6.8	70
112	Carbonic anhydrase inhibitors Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives. *European Journal of Medicinal Chemistry*, **1998**, 33, 739-751	6.8	130
111	Carbonic anhydrase inhibitors Part 52. Metal complexes of heterocyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents in rabbits. *European Journal of Medicinal Chemistry*, **1998**, 33, 247-254	6.8	120
110	The antifungal activity of sulfonylamido derivatives of 2-aminophenoxathiin and related compounds. *European Journal of Medicinal Chemistry*, **1998**, 33, 821-830	6.8	12
109	XAS characterization of the active sites of novel intradiol ring-cleaving dioxygenases: hydroxyquinol and chlorocatechol dioxygenases. *FEBS Letters*, **1998**, 433, 58-62	3.8	14
108	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with heterocyclic mercaptans, sulfenamides, sulfonamides and their metal complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 177-94		23
107	Carbonic anhydrase inhibitors: novel compounds containing S-NH moieties: sulfenamido-sulfonamides, sulfenimido-sulfonamides and their interaction with isozymes I, II and IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 419-42		12
106	The antifungal activity of 2,2′-diamino-4,4′-dithiazole derivatives is due to the possible inhibition of lanosterol-14-alpha-demethylase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 14, 49-68		3
105	Carbonic anhydrase inhibitors: ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozyme I. A novel route to 2,5-disubstituted-1,3,4-thiadiazoles via thioureas, and their interaction with isozymes I, II and IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 103-23		27
104	INHIBITION OF CARBONIC ANHYDRASE ISOZYMES I, II AND IV WITH ARSANILIC ACID DERIVATIVES. *Main Group Metal Chemistry*, **1998**, 21,	1.6	1
103	Sulfonylamido derivatives of 2-aminophenoxathiin-10,10-dioxide and related compounds possess antifungal action due to the possible inhibition of lanosterol-14-alpha-demethylase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 291-310		7
102	Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 267-84		26

101	Synthesis and antifungal activity of metal complexes containing dichloro-tetramorpholino-cyclophosphazatriene. *Metal-Based Drugs*, **1998**, 5, 287-94		3
100	Carbonic Anhydrase Inhibitors. Part 55 Metal Complexes of 1,3,4-Thiadiazole-2-Sulfonamide Derivatives: In Vitro Inhibition Studies With Carbonic Anhydrase Isozymes I, II and IV. *Metal-Based Drugs*, **1998**, 5, 103-14		8
99	Complexes with biologically active ligands. Part 11. Synthesis and carbonic anhydrase inhibitory activity of metal complexes of 4,5-disubstituted-3-mercapto-1,2,4-triazole derivatives. *Metal-Based Drugs*, **1998**, 5, 11-8		3
98	INTERACTION OF ISOZYMES I AND II OF CARBONIC ANHYDRASE WITH Ge(IV) AND Sb(lll) DERIVATIVES. *Main Group Metal Chemistry*, **1997**, 20,	1.6	4
97	SYNTHESIS AND CARBONIC ANHYDRASE INHIBITORY ACTIVITY OF 5-BENZOYLAMIDO- AND 5-(3-NITROBENZOYLAMIDO)- 1,3,4-THIADIAZOLE-2-SULFONAMIDE AND THEIR METAL COMPLEXES. *Main Group Metal Chemistry*, **1997**, 20,	1.6	41
96	Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1997**, 12, 175-90		35
95	Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. *Biochemistry*, **1997**, 36, 10384-92	3.2	246
94	Novel aromatic/heterocyclic sulfonamides and their metal complexes as inhibitors of carbonic anhydrase isozymes I, II and IV. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1997**, 12, 37-51		62
93	Characterization of an intradiol dioxygenase involved in the biodegradation of the chlorophenoxy herbicides 2,4-D and 2,4,5-T. *FEBS Letters*, **1997**, 407, 69-72	3.8	24
92	Purification, biochemical properties and substrate specificity of a catechol 1,2-dioxygenase from a phenol degrading Acinetobacter radioresistens. *FEBS Letters*, **1997**, 416, 61-4	3.8	51
91	Carbonic Anhydrase Inhibitors. Part 46 Inhibition of Carbonic Anhydrase Isozymes I, II and IV With Trifluoromethylsulfonamide Derivatives and Their Zinc(II) and Copper(II) Complexes. *Metal-Based Drugs*, **1997**, 4, 27-34		26
90	Complexes With Biologically Active Ligands. Part 10 Inhibition of Carbonic Anhydrase Isozymes I and II With Metal Complexes of Imidazo[2,1-b]-1,3,4-Thiadiazole-2-Sulfonamide. *Metal-Based Drugs*, **1997**, 4, 19-26		24
89	Carbonic Anhydrase Activators. Part 19 Spectroscopic and Kinetic Investigations for the Interaction of Isozymes I and II With Primary Amines. *Metal-Based Drugs*, **1997**, 4, 221-7		3
88	Complexes with biologically active ligands. Part 9 metal complexes of 5-benzoylamino- and 5-(3-nitrobenzoyl-amino)-1,3,4-thiadiazole-2-sulfonamide as carbonic anhydrase inhibitors. *Metal-Based Drugs*, **1997**, 4, 1-7		7
87	Carbonic anhydrase inhibitors. Part 54: metal complexes of heterocyclic sulfonamides: a new class of antiglaucoma agents. *Metal-Based Drugs*, **1997**, 4, 307-15		3
86	1H NMR ganglioside ceramide resonance region on the differential diagnosis of low and high malignancy of brain gliomas. *Cellular and Molecular Neurobiology*, **1997**, 17, 521-35	4.6	8
85	Carbonic anhydrase inhibitors. Part 43. Schiff bases derived from aromatic sulfonamides: towards more specific inhibitors for membrane-bound versus cytosolic isozymes. *European Journal of Medicinal Chemistry*, **1997**, 32, 445-452	6.8	54
84	Sulfonylamido derivatives of aminoglutethimide and their copper(II) complexes: a novel class of antifungal compounds. *European Journal of Medicinal Chemistry*, **1997**, 32, 901-910	6.8	25

83	Carbonic anhydrase activators. Part 17. Synthesis and activation study of a series of 1-(1,2,4-triazole-(1H)-3-yl)-2,4,6-trisubstituted-pyridinium salts against isozymes I, II and IV. *European Journal of Medicinal Chemistry*, **1997**, 32, 911-918	6.8	27
82	Functionalized Derivatives of Benzocrown Ethers, II. Supramolecular Complexes of L-Amino Acids as Efficient Activators of the Zinc Enzyme Carbonic Anhydrase. *Liebigs Annalen*, **1997**, 1997, 1853-1859		15
81	Predictive Models for the Efficacy of Bioremediation **1997**, 25-37		
80	Complexes With Biologically Active Ligands. Part 6 Ni(II) Coordination Compounds of Hydrazine and Heterocyclic Sulfonamides as Inhibitors of the Zinc Enzyme Carbonic Anhydrase. *Metal-Based Drugs*, **1996**, 3, 143-8		16
79	Carbonic Anhydrase Interaction With Lipothioars Enites: A Novel Class of Isozymes I and II Inhibitors. *Metal-Based Drugs*, **1996**, 3, 263-8		16
78	Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. *European Journal of Medicinal Chemistry*, **1996**, 31, 1001-1010	6.8	146
77	Biophysical investigation of bacterial aromatic extradiol dioxygenases involved in biodegradation processes. *Coordination Chemistry Reviews*, **1995**, 144, 321-345	23.2	19
76	EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios. *BioMetals*, **1994**, 7, 104-8	3.4	6
75	Polymetallic macromolecules are potential contrast agents of improved efficiency. *Magnetic Resonance in Medicine*, **1994**, 31, 58-60	4.4	13
74	Paramagnetic Metal Centers in Proteins Investigated through Heterocorrelated NMR Spectroscopy. *Journal of Magnetic Resonance Series B*, **1994**, 104, 95-98		12
73	Substrate, substrate analogue, and inhibitor interactions with the ferrous active site of catechol 2,3-dioxygenase monitored through XAS studies. *FEBS Letters*, **1994**, 350, 207-12	3.8	10
72	Aliphatic and aromatic inhibitors binding to the active site of catechol 2,3-dioxygenase from Pseudomonas putida mt-2. *FEBS Letters*, **1994**, 343, 56-60	3.8	23
71	X-ray absorption studies on catechol 2,3-dioxygenase from Pseudomonas putida mt2. *Biochemistry*, **1994**, 33, 10777-84	3.2	32
70	Iron-sulfur Proteins: Part II Valence-specific Assignment in Oxidized Hipip through 1H NMR Spectroscopy. *Topics in Molecular Organization and Engineering*, **1994**, 143-157		1
69	Copper-cobalt superoxide dismutase: A re-examination of the 1H NMR spectrum through a novel selectively deuteriated derivative. *Magnetic Resonance in Chemistry*, **1993**, 31, S17-S22	2.1	5
68	Application of 2D 1H NMR spectroscopy to the study of the brain, spinal cord, and sciatic nerve. *Molecular and Chemical Neuropathology*, **1993**, 19, 1-13		7
67	The role of the active site amino acid residues on the catalytic activity of Cu2Zn2SOD. *Molecular and Chemical Neuropathology*, **1993**, 19, 193-204		6
66	Selective interaction of ferricyanide with cluster I of Clostridium pasteurianum 2[Fe4S4] ferredoxin. *FEBS Letters*, **1993**, 332, 268-72	3.8	17

65	Advances in the NMR investigation of paramagnetic molecules in solution. *Coordination Chemistry Reviews*, **1992**, 120, 1-28	23.2	22
64	1H-NMR studies on partially and fully reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. *FEBS Journal*, **1992**, 204, 831-9		45
63	1H NOE studies of oxidized high potential iron sulfur protein II from Ectothiorhodospira halophila. *Inorganica Chimica Acta*, **1991**, 180, 171-175	2.7	25
62	A thermodynamic and spectroscopic study of the complexes of the undecapeptide Substance P, of its N-terminal fragment and of model pentapeptides containing two prolyl residues with copper ions. *Journal of the Chemical Society Dalton Transactions*, **1991**, 1651		10
61	Proton NMR spectra of oxidized high-potential iron-sulfur protein (HiPIP) from Rhodocyclus gelatinosus. A model for oxidized HiPIPs. *Inorganic Chemistry*, **1991**, 30, 4517-4524	5.1	61
60	Proton NMR spectroscopy and the electronic structure of the high potential iron-sulfur protein from Chromatium vinosum. *Journal of the American Chemical Society*, **1991**, 113, 1237-1245	16.4	104
59	2D 1H NMR studies of oxidized 2(Fe4S4) ferredoxin from Clostridium pasteurianum. *FEBS Letters*, **1991**, 289, 253-6	3.8	40
58	The unusual behavior of the inhibitor S(+)(1-amino-2-phenylethyl)phosphonic acid towards carboxypeptidase A. *Journal of Inorganic Biochemistry*, **1990**, 40, 227-35	4.2	11
57	EXAFS investigation on the iron(III) binding sites of hen phosvitin. *Inorganic Chemistry*, **1990**, 29, 124-127	5.1	8
56	Proton NMR studies of the oxidized and partially reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. *Inorganic Chemistry*, **1990**, 29, 1874-1880	5.1	36
55	1H NMR studies of Chromatium vinosum cytochrome cM*Archives of Biochemistry and Biophysics*, **1990**, 282, 84-90	4.1	12
54	Proton NOE studies on dicopper(II) dicobalt(II) superoxide dismutase. *Inorganic Chemistry*, **1989**, 28, 4650-4656	5.1	133
53	CD and EXAFS study of the interaction between phosvitin and copper(II) ions. *Journal of Inorganic Biochemistry*, **1988**, 34, 221-239	4.2	8
52	Nuclear relaxation in the magnetic coupled system Cu2Co2SOD. Histidine-44 is detached upon anion binding. *Journal of the American Chemical Society*, **1987**, 109, 2328-2334	16.4	55
51	Ytterbium(III) as a CD probe for the investigation of the metal binding sites of transferrins. *Inorganica Chimica Acta*, **1986**, 124, L15-L17	2.7	6
50	The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives.. *Journal of Biological Chemistry*, **1986**, 261, 1139-1146	5.4	12
49	Investigation of Cu2Co2SOD and its anion derivatives. Proton NMR and electronic spectra. *Journal of the American Chemical Society*, **1985**, 107, 4391-4396	16.4	80
48	Multinuclear NMR investigation of the metal binding sites of transferrins. *Journal of Molecular Structure*, **1984**, 113, 191-200	3.4	2

47	Investigation of zinc-deprived bovine superoxide dismutase. *Inorganica Chimica Acta*, **1984**, 91, 109-111	2.7	5
46	Investigation of the copper?magnesium?alkaline phosphatase system. *Inorganica Chimica Acta*, **1983**, 78, 19-22	2.7	4
45	Carbonic anhydrase: An insight into the zinc binding site and into the active cavity through metal substitution **1982**, 45-92		114
44	Cooperative phenomena in polynuclear metalloproteins. *Inorganica Chimica Acta*, **1982**, 62, 15-22	2.7	4
43	Different behavior of sulfonamides with respect to copper-substituted bovine and human carbonic anhydrases. *Journal of Inorganic Biochemistry*, **1982**, 16, 155-60	4.2	8
42	Binding sites of anions in superoxide dismutase. *Journal of the American Chemical Society*, **1981**, 103, 7779-7783	16.4	34
41	Intramolecular ring-stacking interaction between caffeine and bis(1,10-phenanthroline)copper(II) ion: 1H NMR and calorimetric investigations. *Inorganica Chimica Acta*, **1981**, 56, 73-77	2.7	4
40	A new class of inhibitors capable of binding both the acidic and alkaline forms of carbonic anhydrase. *Biochimica Et Biophysica Acta (BBA) - Protein Structure*, **1981**, 668, 16-26		18
39	Complexes between pilocarpine and cobalt(II), nickel(II), copper(II), and zinc(II) ions. *Journal of Pharmaceutical Sciences*, **1980**, 69, 1220-2	3.9	3
38	spectroscopic Investigation on a New Class of Inhibitors which Bind either the Acidic or Basic Form of Cobalt Substituted Carbonic Anhydrase. *Inorganica Chimica Acta*, **1980**, 40, X86	2.7	
37	The acid-base equilibria of carbonic anhydrase. *Inorganica Chimica Acta*, **1980**, 46, 85-89	2.7	26
36	Superoxide dismutase-thiocyanate: a study of the binding sites of anions on copper(II) in superoxide dismutase. *Journal of the American Chemical Society*, **1980**, 102, 7349-7353	16.4	28
35	Effects of planar and tetrahedral distortions on the ESR parameters of bis(salicylaldiminato)copper(II) complexes. *Inorganic Chemistry*, **1980**, 19, 2198-2200	5.1	47
34	Some Structural Aspects of Carbonic Anhydrase. *Proceedings in Life Sciences*, **1980**, 151-153		2
33	The electronic spectra of cobalt(II) bovine carbonic anhydrase. *Inorganica Chimica Acta*, **1979**, 36, L431-L432	2.7	8
32	Characterization of oxovanadium(IV) substituted bovine carbonic anhydrase B. *Inorganica Chimica Acta*, **1979**, 36, 9-12	2.7	11
31	Six-coordinate copper complexes wlth g. *Coordination Chemistry Reviews*, **1979**, 29, 67-84	23.2	48
30	Static□dynamic distortions of the tris(1,2-diaminoethane)copper(II) cation [Cu(en)3]2+. Crystal structures of the salts [Cu(en)3][SO4] at 120 K and of [Cu(en)3]Cl2□0.75 en at 298 K. *Journal of the Chemical Society Dalton Transactions*, **1979**, 1409-1414		22

29	31P NMR spectra of paramagnetic MBr2 (OPPh3)2 complexes. A breakdown in the validity of the Solomon-Bloembergen equations. *Inorganic and Nuclear Chemistry Letters*, **1979**, 15, 89-91		4
28	Binding affinity of bicarboxylate ions for cobalt (II) bovine carbonic anhydrase. *Bioinorganic Chemistry*, **1978**, 9, 93-100		23
27	X-ray and ESR investigation of an elongated octahedral tris-(1, 2-diaminoethane) copper (II) complex. *Solid State Communications*, **1978**, 26, 749-751	1.6	3
26	Single-crystal ESR spectra of copper(II) complexes with geometries intermediate between a square pyramid and a trigonal bipyramid. *Inorganic Chemistry*, **1978**, 17, 3194-3197	5.1	100
25	Spectroscopic investigation of copper(II) bovine carbonic anhydrase and its inhibitor derivatives. *Journal of the Chemical Society Dalton Transactions*, **1978**, 1269		21
24	Characterization of cobalt(II) bovine carbonic anhydrase and of its derivatives. *Journal of the American Chemical Society*, **1978**, 100, 4873-4877	16.4	129
23	Evidence of exchangeable protons in the acidic form of manganese(II) bovine carbonic anhydrase B. *FEBS Letters*, **1978**, 87, 92-4	3.8	8
22	A 31P NMR study of phosphate in presence of cobalt(II)- and copper(II)- substituted bovine carbonic anhydrase B. *FEBS Letters*, **1978**, 93, 251-4	3.8	9
21	Evidence of exchangeable protons in the donor groups of the acidic form of cobalt bovine carbonic anhydrase B. *Biochemical and Biophysical Research Communications*, **1977**, 78, 158-60	3.4	27
20	Carbon-13 longitudinal relaxation times of acetate ion in the presence of metal-substituted bovine carbonic anhydrases. *Journal of the Chemical Society Dalton Transactions*, **1977**, 1962		11
19	Interaction of cobalt(II) bovine carbonic anhydrase with aniline, benzoate, and anthranilate. *Journal of the American Chemical Society*, **1977**, 99, 581-4	16.4	27
18	Jahn-Teller distortions of tris(ethylenediamine)copper(II) complexes. *Inorganic Chemistry*, **1977**, 16, 1973-1976	5.1	54
17	Interactions between alpha-amino acids and cobalt(II) bovine-carbonic anhydrase. *Bioinorganic Chemistry*, **1977**, 7, 225-31		9
16	Single crystal polarized electronic spectra of a five-coordinate macrocyclic complex of nickel(II). *Inorganica Chimica Acta*, **1977**, 21, 223-227	2.7	12
15	Stereochemistry of cobalt(II) in cobalt bovine carbonic anhydrase and its derivatives. *Inorganica Chimica Acta*, **1977**, 22, L23-L24	2.7	11
14	Proton relaxation of water solutions containing copper carbonic anhydrase. *Inorganica Chimica Acta* , **1977**, 23, L15-L16	2.7	10
13	Single crystal electronic spectra and ligand field parameters of some nickel(II) amine-isothiocyanato and amine-nitrito complexes. *Inorganic Chemistry*, **1976**, 15, 203-207	5.1	34
12	Interaction of cobalt-bovine carbonic anhydrase with the acetate ion. *Biochimica Et Biophysica Acta - Biomembranes*, **1976**, 452, 239-44	3.8	28

11	Ligand Field Parameters. *Israel Journal of Chemistry*, **1976**, 15, 189-199	3.4	10
10	13C Nmr spectra of hexakis pyridine-N-oxide cobalt(II) and nickel(II) complexes. *Inorganica Chimica Acta*, **1976**, 19, 201-202	2.7	4
9	A comment on the Jahn-Teller effect in the complex K2PbCu(NO2)6. *Inorganica Chimica Acta*, **1975**, 13, L5-L6	2.7	4
8	Single crystal polarized electronic spectra of the complex bis(N-t-butylpyrrole-2-carbaldimino)cobalt(II). *Inorganica Chimica Acta*, **1975**, 13, 145-148	2.7	4
7	Ligand field interpretation of high-spin trigonal-bipyramidal cobalt(II) complexes. *Inorganic Chemistry*, **1975**, 14, 812-815	5.1	30
6	Single crystal ESR study of the Cu(en)3SO4 complex. *Inorganica Chimica Acta*, **1974**, 11, L17-L19	2.7	15
5	Proton magnetic resonance spectra of six-coordinate iron(II), cobalt(II), and nickel(II) complexes with pyridine-n-oxide and benzamide. *Inorganica Chimica Acta*, **1972**, 6, 185-187	2.7	13
4	Antiglaucoma Carbonic Anhydrase Inhibitors as Ophthalomologic Drugs139-153		20
3	Zinc Binding Functions in the Design of Carbonic Anhydrase Inhibitors39-72		9
2	Drug Design Studies of Carbonic Anhydrase Activators473-486		6
1	Carbonic Anhydrase Activators		6